Rachel Haurwitz, Caribou Biosciences CEO

Cari­bou says par­tial HLA match­ing will im­prove dura­bil­i­ty of re­sponse to cell ther­a­py 

CHICA­GO — Cari­bou’s off-the-shelf cell ther­a­py ap­pears poised to break free from the rapid re­laps­es that have plagued oth­er off-the-shelf cell ther­a­pies, ac­cord­ing to a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.